VIGL - Vigil Neuroscience, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
VIGL price evolution
VIGL
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $90.22 | $106.54 | $121.91 | $139.85 |
| Long term investments | ||||
| Property, plant & equipment | $17.03 | $17.48 | $17.94 | $18.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $108.46 | $125.08 | $140.86 | $159.16 |
| Current liabilities | ||||
| Accounts payable | $1.42 | $1.49 | $1.95 | $1.3 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $10.76 | $8.6 | $11.66 | $10.14 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $23.19 | $21.3 | $24.61 | $23.32 |
| Shareholders' equity | ||||
| Retained earnings | -$263.94 | -$242.71 | -$222.77 | -$200.6 |
| Other shareholder equity | -$0.03 | -$0.03 | -$0.01 | -$0.06 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $121.91 | $197.81 | $97.48 | $25.3 |
| Long term investments | ||||
| Property, plant & equipment | $17.94 | $1.4 | $1.27 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $140.86 | $200.39 | $102.44 | $25.3 |
| Current liabilities | ||||
| Accounts payable | $1.95 | $1.94 | $3.98 | $1.11 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $11.66 | $11.31 | $9.88 | $2 |
| Long term debt | $0.02 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $24.61 | $11.31 | $9.95 | $6.54 |
| Shareholders' equity | ||||
| Retained earnings | -$222.77 | -$140.13 | -$71.83 | -$28.55 |
| Other shareholder equity | -$0.01 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $17.64 | $17.04 | $15.33 | $12.98 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.16 | $0.03 | $0 | |
| Net income | ||||
| Net income | -$17.5 | -$17.02 | -$15.33 | -$12.98 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $42.41 | $27.21 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.83 | -$1.31 | ||
| Net income | ||||
| Net income | -$43.28 | -$28.55 | ||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 30 Apr 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.65 | -$0.23 | -$0.14 | -$0.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $161.15 | $89.86 | $90.19 | $107.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $112.44 | $57.49 | $71.9 | $68.2 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | ||
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.2 | -$0.5 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $107.75 | $29.83 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $68.2 | $24.15 | ||
News
|
Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer's...
Benzinga · via Yahoo Finance
22 Jul 2024
|
|
3 Penny Stocks With the Power to 10X Your $1k Investment: June Edition
InvestorPlace · via Yahoo Finance
21 Jun 2024
|
|
Vigil Neuroscience, Inc. (VIGL): Is This the Best Biotech Penny Stock to Buy...
Insider Monkey · via Yahoo Finance
21 Jun 2024
|
|
All You Need to Know About Vigil Neuroscience (VIGL) Rating Upgrade to Buy
Zacks · via Yahoo Finance
21 May 2024
|
|
Arm initiated, SQM downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance
18 Oct 2023
|
|
Vigil Neuroscience Touts Positive Healthy Volunteer Data From Lead Program In Rare Neurological...
Benzinga via Yahoo Finance
2 Nov 2022
|
|
How Much Upside is Left in Vigil Neuroscience, Inc. (VIGL)? Wall Street Analysts Think 133%
Zacks via Yahoo Finance
29 Aug 2022
|
|
Wall Street Analysts Believe Vigil Neuroscience, Inc. (VIGL) Could Rally 167%: Here's is How to...
Zacks via Yahoo Finance
12 Aug 2022
|
Fundamentals
| Market cap | $112.77M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 37.59M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$62.83M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -1.79 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.67 |
|---|---|
| ROA | -47.11% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.39 |
| Quick ratio | N/A |